In June 2014, The Spectranetics Corporation acquired AngioScore Inc. in a $230 million cash purchase, along with contingent commercial and regulatory milestone payments. FaegreBD's corporate team represented Spectranetics in the deal. The transaction was funded with the proceeds from a $230 million public offering of convertible notes, with FaegreBD advising on the offering.
AngioScore is a leading developer, manufacturer and marketer of cardiovascular specialty balloons based in Fremont, California. The acquisition enhanced Spectranetics' cardiovascular medical device product portfolio and expanded its market opportunities.